Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...
Zacks Investment Research on MSN2d
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's DiseaseJohnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel ...
Treatment with deucravacitinib in patients with active PsA showed higher response rates and improvement in quality of life ...
Johnson & Johnson's Tremfya gains FDA approval for Crohn's disease, backed by Phase 3 trial data and demonstrating ...
Squibb announced positive data from the Phase 3 POETYK PsA-2 trial evaluating the efficacy and safety of Sotyktu in adults ...
STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S.
The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction options for adults with moderate to severe active Crohn disease.
Horsham: Johnson & Johnson has announced that the Company ahs received approval from the U.S. Food and Drug Administration ...
Tremfya is the first and only IL-23 inhibitor with both subcutaneous and intravenous induction options for adults with moderately to severely active Crohn disease in the United States.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback